Head to head
Tirzepatide against Dulaglutide
Two once-weekly injections from the same manufacturer, one a GIP and GLP-1 dual agonist and one a GLP-1 agonist. They have not been randomised against each other, though each has been compared with semaglutide, which is how most indirect rankings of this class get built.
Column A
TirzepatideTirzepatide (dual GIP/GLP-1 receptor agonist)
A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists.
Column B
DulaglutideDulaglutide (GLP-1 receptor agonist)
A once-weekly GLP-1 receptor agonist for type 2 diabetes with demonstrated cardiovascular risk reduction.
Side by side, on the facts we can check
| Attribute | Tirzepatide | Dulaglutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea) | FDA-approved (Trulicity) |
| Half-life | ~5 days | ~5 days |
| Molecular weight | 4,813.5 Da | ~59,700 Da |
| Mechanism | Simultaneously activates GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, reducing glucagon, delaying gastric emptying, and reducing appetite. The GIP component is thought to add complementary metabolic effects. | Activates the GLP-1 receptor to enhance glucose-dependent insulin release, suppress glucagon, and slow gastric emptying. |
| Human studies cited | 4 | 2 |
| Legal status, US | FDA-approved, prescription only | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Tirzepatide and Dulaglutide?
Tirzepatide: A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists. Dulaglutide: A once-weekly GLP-1 receptor agonist for type 2 diabetes with demonstrated cardiovascular risk reduction.
Which has stronger research evidence, Tirzepatide or Dulaglutide?
This database does not grade compounds. It counts what was run in people: 4 of the 4 studies cited on the Tirzepatide profile were human work, against 2 of 2 for Dulaglutide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Tirzepatide and Dulaglutide FDA-approved?
Tirzepatide: FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea). Dulaglutide: FDA-approved (Trulicity).
Related posts
Blog articles that cover Tirzepatide or Dulaglutide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
- Metabolic / Sep 8, 2026 / 9 minMariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1 Agonist and GIP Blocker, Explained
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.